TY - JOUR
T1 - In vivo visualization of α-synuclein deposition by carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy]benzoxazole positron emission tomography in multiple system atrophy
AU - Kikuchi, Akio
AU - Takeda, Atsushi
AU - Okamura, Nobuyuki
AU - Tashiro, Manabu
AU - Hasegawa, Takafumi
AU - Furumoto, Shozo
AU - Kobayashi, Michiko
AU - Sugeno, Naoto
AU - Baba, Toru
AU - Miki, Yasuo
AU - Mori, Fumiaki
AU - Wakabayashi, Koichi
AU - Funaki, Yoshihito
AU - Iwata, Ren
AU - Takahashi, Shoki
AU - Fukuda, Hiroshi
AU - Arai, Hiroyuki
AU - Kudo, Yukitsuka
AU - Yanai, Kazuhiko
AU - Itoyama, Yasuto
N1 - Funding Information:
Grant for ‘the Research Committee for Ataxic Diseases’ of the Research on Measures for Intractable Diseases from the Ministry of Health, Labour and Welfare, Japan (partial).
PY - 2010/6
Y1 - 2010/6
N2 - The histopathological hallmark of multiple system atrophy is the appearance of intracellular inclusion bodies, named glial cytoplasmic inclusions, which are mainly composed of α-synuclein fibrils. In vivo visualization of α-synuclein deposition should be used for the diagnosis and assessment of therapy and severity of pathological progression in multiple system atrophy. Because 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole could stain α-synuclein-containing glial cytoplasmic inclusions in post-mortem brains, we compared the carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography findings of eight multiple system atrophy cases to those of age-matched normal controls. The positron emission tomography data demonstrated high distribution volumes in the subcortical white matter (uncorrected P < 0.001), putamen and posterior cingulate cortex (uncorrected P < 0.005), globus pallidus, primary motor cortex and anterior cingulate cortex (uncorrected P < 0.01), and substantia nigra (uncorrected P < 0.05) in multiple system atrophy cases compared to the normal controls. They were coincident with glial cytoplasmic inclusion-rich brain areas in multiple system atrophy and thus, carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]- 6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography is a promising surrogate marker for monitoring intracellular α-synuclein deposition in living brains.
AB - The histopathological hallmark of multiple system atrophy is the appearance of intracellular inclusion bodies, named glial cytoplasmic inclusions, which are mainly composed of α-synuclein fibrils. In vivo visualization of α-synuclein deposition should be used for the diagnosis and assessment of therapy and severity of pathological progression in multiple system atrophy. Because 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole could stain α-synuclein-containing glial cytoplasmic inclusions in post-mortem brains, we compared the carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]-6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography findings of eight multiple system atrophy cases to those of age-matched normal controls. The positron emission tomography data demonstrated high distribution volumes in the subcortical white matter (uncorrected P < 0.001), putamen and posterior cingulate cortex (uncorrected P < 0.005), globus pallidus, primary motor cortex and anterior cingulate cortex (uncorrected P < 0.01), and substantia nigra (uncorrected P < 0.05) in multiple system atrophy cases compared to the normal controls. They were coincident with glial cytoplasmic inclusion-rich brain areas in multiple system atrophy and thus, carbon-11-labelled 2-[2-(2-dimethylaminothiazol-5-yl)ethenyl]- 6-[2-(fluoro)ethoxy] benzoxazole positron emission tomography is a promising surrogate marker for monitoring intracellular α-synuclein deposition in living brains.
KW - Glial cytoplasmic inclusion
KW - Lewy body
KW - Parkinson's disease
KW - Pittsburgh compound B
KW - β-amyloid
UR - http://www.scopus.com/inward/record.url?scp=77952982672&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77952982672&partnerID=8YFLogxK
U2 - 10.1093/brain/awq091
DO - 10.1093/brain/awq091
M3 - Article
C2 - 20430832
AN - SCOPUS:77952982672
SN - 0006-8950
VL - 133
SP - 1772
EP - 1778
JO - Brain
JF - Brain
IS - 6
ER -